Corvus Pharmaceuticals Reports Q3 2026 Financial Results and Clinical Pipeline Updates
Corvus Pharmaceuticals reported a net loss of $20.3 million for the third quarter of 2026, compared to $10.2 million in the prior year period. The increased loss is primarily attributed to rising research and development expenses, which climbed to $17.8 million due to higher clinical trial costs for soquelitinib and expanded personnel requirements. The company maintains a strong liquidity position with $202.9 million in cash and marketable securities, providing a projected cash runway into the second quarter of 2028. Key clinical milestones include an anticipated futility analysis for its Phase 3 PTCL trial in Q1 2027 and top-line data from the SEERA-1 atopic dermatitis trial expected in Q3 2027.
Topics: cash runway clinical trial progress net loss Phase 3 enrollment R&D expense increase